Sumatriptan (Auro-sumatriptan, Surogran)
Sumatriptan
Aurogen South Africa (Pty) Ltd
Registration
- Applicant
- Aurogen South Africa (Pty) Ltd
- Registrations
- 4
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Auro-sumatriptan tablets 50 MG EACH TABLET CONTAINS SUMATRIPTAN SUCCINATE EQUIVALENT TO SUMATRIPTAN 50,0 mg | 50 mgTablets | 42026942/7.3/0269 | Registered | Not determined | None |
| Auro-sumatriptan tablets 100 MG EACH TABLET CONTAINS SUMATRIPTAN SUCCINATE EQUIVALENT TO SUMATRIPTAN 100,0 mg | 100 mgTablets | 42027042/7.3/0270 | Registered | Not determined | None |
| Surogran 50 MG EACH TABLET CONTAINS SUMATRIPTAN SUCCINATE EQUIVALENT TO SUMATRIPTAN 50,0 mg | 50 mg | 42036742/7.3/0367 | Registered | Not determined | None |
| Surogran 100 MG EACH TABLET CONTAINS SUMATRIPTAN SUCCINATE EQUIVALENT TO SUMATRIPTAN 100,0 mg | 100 mg | 42036842/7.3/0368 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Sumatriptan
- except when in oral solid dosage forms providing 50 mg or less and presented as packs of no more than two oral solid dosage forms, indicated for the acute relief of migraine attacks, with or without aura, in patients previously diagnosed by a medical practitioner and initiated on treatment with sumatriptan. (S2)
Consolidated Schedules 06 July 2026, lines 8060 to 8062
S2: Sumatriptan
- when in oral solid dosage forms providing 50 mg or less and presented as packs of no more than two oral solid dosage forms, indicated for the acute relief of migraine attacks, with or without aura, in patients previously diagnosed by a medical practitioner and initiated on treatment with sumatriptan. (S4)
Consolidated Schedules 06 July 2026, lines 2683 to 2685
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
1-[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
Drag to rotate. Structure from PubChem CID 5358.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.